Health Condition 1: C538- Malignant neoplasm of overlappingsites of cervix uteri
Conditions
Interventions
None listed
Sponsors
Chittaranjan National Cancer Institute
Eligibility
Inclusion criteria
Inclusion criteria: 1.Patients of cervical cancer sent from multidisciplinary tumor board after being proved on histopathology (squamous cell or adenocarcinoma) with FIGO stage IB2 to III 2.Eastern Cooperative Oncology Group performance status upto 2 3.Hemoglobin >10 gm%, Total leukocyte count > 4000 cells/cmm, Platelet count > 1,00,000 cells/cmm (initially or after correction by blood transfusion). 4.Liver function test- AST Kidney function test- Serum creatinine 50 ml/min 5.Patient with no history or current clinical evidence of any hematological or bleeding disorders 6.No history of drug use which results in hematological toxicity 7.HBsAg, Anti-HCV, HIV-I & -II Antibody non-reactive patients.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the feasibility of delineating HR-CTV on CT image following IBS-GEC ESTRO-ABS recommendations & Pre- & Post-EBRT MRI images. Computation of target coverage along with the doses received at Point A. To compare the doses received by bladder, rectum & bowel as per volume-based dose prescription and Point A-based dose prescription. Timepoint: At baseline | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess the treatment response & toxicity with special attention to Gastrointestinal (GI) & Genitourinary(GU) toxicity. Timepoint: At baseline,4 weeks,8weeks,12 weeks,6months,yearly | — |
Countries
India
Contacts
Public ContactDebarshi Lahiri
Chittaranjan National Cancer Institute
Outcome results
None listed